aso3
Small moleculeexperimental
Clinical trial activity
4 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2012 (NCT01573312)
Timeline
Indications
Mechanism of action
- UnclearImmunity, active
Unclear immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aso3
- aso3
- aso3b1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06560151 | Phase 2 | Aug 21, 2024 | Department of Health and Human Services, ICON, Rho, Inc. |
| NCT05007951 | Phase 3 | Aug 30, 2021 | Coalition for Epidemic Preparedness Innovations, GlaxoSmithKline, International Vaccine Institute, Korea University, SK Bioscience Co., Ltd. |
| NCT01666652 | Phase 1 | Sep 1, 2012 | GlaxoSmithKline, United States Army |
| NCT01573312 | Phase 1 | Jun 1, 2012 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 2 | 0 | 2 | 2012 |
| Coalition for Epidemic Preparedness Innovations | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Department of Health and Human Services | Government | 1 | 1 | 1 | 2024 |
| ICON | For profit | 1 | 0 | 1 | 2024 |
| International Vaccine Institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Korea University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2012 |
| Rho, Inc. | For profit | 1 | 0 | 1 | 2024 |
| SK Bioscience Co., Ltd. | For profit | 1 | 1 | 1 | 2021 |
| United States Army | Government | 1 | 1 | 1 | 2012 |
10 organizations
Page 1 / 1